Non-small cell lung cancer
Conditions
Interventions
Lymph node lesions + organ lesions + other lesions:Radiation therapy
Lung lesions + organ lesions + bone metastasis lesions:Radiation therapy
Lymph node lesions + visceral organ lesions + other lesions:Radiation therapy
Lung lesions + Lymph node lesions + visceral organ lesions:Radiation therapy
Lung lesions + visceral organ lesions+other lesions:Radiation therapy
Lung lesions + Lymph node lesions+bone lesions:Radiation therapy
Lung lesions + Lymph node lesions+other lesions:Radiation therapy
Sponsors
The Second Affiliated Hospital of the Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Non-small cell lung cancer (NSCLC) initially diagnosed by pathological histology; 2.with 3-6 metastases; 3.no brain metastasis or stable brain lesions; 4.negative for driver genes (including EGFR, ALK, ROS1, BRAF, MET, RET genes); 5.Eastern Cooperative Oncology Group (ECOG) performance status score: 0-1, with an expected survival of more than 3 months; 6.age between 18-75 years; 7.PET-CT assessment (including FDG and FMISO, not mandatory); 8.no contraindications for immunotherapy and radiotherapy; 9.signed informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients with severe dysfunction of vital organs (heart, liver, kidneys); 2.those with other malignant tumors; 3.uncontrolled heart disease or myocardial infarction within the last 6 months; 4.history of mental illness; 5.other conditions deemed unsuitable for participation in the study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Abscopal response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Duration of Response;Immunotherapy-related adverse reactions;Progression-Free Survival (PFS);Objective Response Rate; | — |
Countries
China
Contacts
Public Contactsunjianguo
The Second Affiliated Hospital of the Army Medical University
Outcome results
None listed